Molecular Partners Presents Interim Safety And Mechanistic Data From Ongoing Phase 1 Trial Of MP0317 For Treatment of Solid Tumors
Molecular Partners Presents Interim Safety And Mechanistic Data From Ongoing Phase 1 Trial Of MP0317 For Treatment of Solid Tumors
分子夥伴公司提供正在進行的MP0317治療實體腫瘤第一階段試驗的臨時安全性和機械學數據
First clinical observation of tumor localized CD40 activation provided by MP0317
No systemic or dose-limiting toxicities observed, a key parameter for CD40 agents
Dose escalation remains ongoing with study recruitment anticipated to complete in 1H 2023
MP0317提供腫瘤局部CD40激活的首次臨牀觀察
沒有觀察到系統性或劑量限制性毒性,這是CD40藥物的關鍵參數
劑量遞增仍在進行中,研究招募預計將於2023年上半年完成
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR : Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the presentation of positive interim results from the ongoing Phase 1 trial of the company's MP0317 (FAP X CD40) program for the treatment of solid tumors at...
瑞士蘇黎世-施利倫和馬薩諸塞州康科德,2022年11月10日(Global Newswire)--根據第53條特別宣佈:分子夥伴公司((...
登入免費觀看全文
登入/註冊